| Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines | | |
| Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology | | |
| Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations | | |
| Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective | | |
| Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars | | 2022 |
| Biosimilars: Harmonizing the Approval Guidelines | | 2022 |
| Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials | European Journal of Hospital Pharmacy | |
| Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies | BioDrugs | |
| The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland | BioDrugs | 2022 |
| Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective | | |
| Perspectives toward biosimilars among oncologists: A Malaysian survey | Journal of Oncology Pharmacy Practice | |
| Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions | International Journal of Molecular Sciences | 2022 |
| Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience | BioDrugs | |
| Critical Appraisal and Future Outlook on Anti-Inflammatory Biosimilar Use in Chronic Immune-Mediated Inflammatory Diseases | Seminars in Arthritis and Rheumatism | 2022 |
| Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get? | Drug Discovery Today | 2022 |
| Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis. | Dermatology and Therapy | 2022 |
| Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review | BioDrugs | 2021 |
| An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. | Ophthalmology and Therapy | 2022 |
| The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. | Seminars in Arthritis and Rheumatism | 2021 |
| Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies. | Advances in Therapy | 2022 |
| A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program. | Frontiers in Medicine | 2022 |
| Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution. | PLoS ONE | 2022 |
| Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17. | Clinical Drug Investigation | 2022 |
| Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor | Journal of Exploratory Research in Pharmacology | 2020 |
| Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? | Drugs | 2021 |
| Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review | British Journal of Clinical Pharmacology | 2021 |
| Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial | JAMA Ophthalmology | 2021 |
| Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective | Drugs | 2021 |
| A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers | Expert Opinion on Biological Therapy | 2021 |
| Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review | BioDrugs | 2021 |
| Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial | Expert Opinion on Biological Therapy | 2021 |
| Biosimilar Uptake: The Importance of Healthcare Provider Education | Pharmaceutical Medicine | 2021 |
| Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease | Digestive Diseases and Sciences | 2021 |
| Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects | RMD Open | 2021 |
| Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars | European Journal of Clinical Pharmacology | 2021 |
| Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®) | Animal Cells and Systems | 2021 |
| Letter to the Editor Regarding "The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence" | Advances in Therapy | 2021 |
| Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities | Pharmaceuticals | 2021 |
| The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable | Advances in Therapy | 2021 |
| Effective tools to manage biosimilars prescription: The Italian experience | Health Policy and Technology | 2021 |
| Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents? | Pharmacoepidemiology and Drug Safety | 2021 |
| Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars | BioDrugs | 2020 |
| Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of "Non-medical Switch" | Digestive Diseases and Sciences | 2020 |
| Substitution médicamenteuse – Enquête sur les pratiques en pharmacie hospitalière | Pharmacien Hospitalier Et Clinicien | 2020 |
| Biosimilar medicines: Why the science matters | Health Policy and Technology | 2020 |
| Biosimilars, a new era in rheumatology in Spain | Reumatología Clínica (English Edition) | 2020 |
| Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice | Expert Review of Clinical Immunology | 2020 |
| Potential Cost-Savings From the Use of the Biosimilars in Slovakia | Frontiers in Public Health | 2020 |
| Explaining biosimilars and how reverse engineering plays a critical role in their development | Expert Opinion on Drug Discovery | 2020 |
| Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review | Pharmaceuticals | 2020 |
